← Centessa Pharmaceuticals PLC ADR overview

Centessa Pharmaceuticals PLC ADR vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Centessa Pharmaceuticals PLC ADR (CNTA)

Q2 2026
▲4

Centessa's $7.8B Lilly Buyout Closes; Biotech M&A Boom Continues

  • UK court approves Lilly's $7.8B Centessa acquisition The UK High Court approved Eli Lilly's $7.8 billion buyout of Centessa. Shareholders get $38 per share in cash plus a contingent value right worth up to $9 more if milestones are met. This locked in the deal price and removed uncertainty, pushing CNTA toward the buyout value.

    This is the key regulatory approval that made the buyout final and set the exact payout for shareholders.

  • Lilly completes Centessa acquisition; CNTA delisted Eli Lilly closed its acquisition of Centessa on June 24, 2026. CNTA shares stopped trading on Nasdaq, and shareholders received the cash and CVR payout. This is the final step that turned the buyout into real money for investors.

    This is the event that ended CNTA's life as a public stock and delivered the buyout proceeds to shareholders.

  • Biopharma M&A hits six-year high, validating Centessa's sale PwC reported Q1 2026 pharma deal value topped $65 billion, the strongest since 2020, driven by a huge patent cliff. Lilly's $7.8 billion Centessa purchase was a highlight. This confirms Centessa was bought in a hot market, supporting the deal price and CVR potential.

    It shows the broader M&A boom that made Centessa's buyout possible and validates the valuation.

  • Biotech named hottest market group after Centessa deal Jim Cramer called biotech the hottest group, citing a 51% biotech ETF gain and a deal surge under new FDA leadership. He noted Lilly's acquisitions, including Centessa. This keeps investor attention on biotech M&A, which can lift CVR expectations and similar stocks.

    It reflects ongoing market enthusiasm for biotech deals, which supports the value of Centessa's CVR and the sector.

June 2026
▲4

Centessa's $7.8B Lilly Buyout Closes; Biotech M&A Boom Continues

  • UK court approves Lilly's $7.8B Centessa acquisition The UK High Court approved Eli Lilly's $7.8 billion buyout of Centessa. Shareholders get $38 per share in cash plus a contingent value right worth up to $9 more if milestones are met. This locked in the deal price and removed uncertainty, pushing CNTA toward the buyout value.

    This is the key regulatory approval that made the buyout final and set the exact payout for shareholders.

  • Lilly completes Centessa acquisition; CNTA delisted Eli Lilly closed its acquisition of Centessa on June 24, 2026. CNTA shares stopped trading on Nasdaq, and shareholders received the cash and CVR payout. This is the final step that turned the buyout into real money for investors.

    This is the event that ended CNTA's life as a public stock and delivered the buyout proceeds to shareholders.

  • Biopharma M&A hits six-year high, validating Centessa's sale PwC reported Q1 2026 pharma deal value topped $65 billion, the strongest since 2020, driven by a huge patent cliff. Lilly's $7.8 billion Centessa purchase was a highlight. This confirms Centessa was bought in a hot market, supporting the deal price and CVR potential.

    It shows the broader M&A boom that made Centessa's buyout possible and validates the valuation.

  • Biotech named hottest market group after Centessa deal Jim Cramer called biotech the hottest group, citing a 51% biotech ETF gain and a deal surge under new FDA leadership. He noted Lilly's acquisitions, including Centessa. This keeps investor attention on biotech M&A, which can lift CVR expectations and similar stocks.

    It reflects ongoing market enthusiasm for biotech deals, which supports the value of Centessa's CVR and the sector.

Latest
▲4

Centessa's $7.8B Lilly Buyout Closes; Biotech M&A Boom Continues

  • UK court approves Lilly's $7.8B Centessa acquisition The UK High Court approved Eli Lilly's $7.8 billion buyout of Centessa. Shareholders get $38 per share in cash plus a contingent value right worth up to $9 more if milestones are met. This locked in the deal price and removed uncertainty, pushing CNTA toward the buyout value.

    This is the key regulatory approval that made the buyout final and set the exact payout for shareholders.

  • Lilly completes Centessa acquisition; CNTA delisted Eli Lilly closed its acquisition of Centessa on June 24, 2026. CNTA shares stopped trading on Nasdaq, and shareholders received the cash and CVR payout. This is the final step that turned the buyout into real money for investors.

    This is the event that ended CNTA's life as a public stock and delivered the buyout proceeds to shareholders.

  • Biopharma M&A hits six-year high, validating Centessa's sale PwC reported Q1 2026 pharma deal value topped $65 billion, the strongest since 2020, driven by a huge patent cliff. Lilly's $7.8 billion Centessa purchase was a highlight. This confirms Centessa was bought in a hot market, supporting the deal price and CVR potential.

    It shows the broader M&A boom that made Centessa's buyout possible and validates the valuation.

  • Biotech named hottest market group after Centessa deal Jim Cramer called biotech the hottest group, citing a 51% biotech ETF gain and a deal surge under new FDA leadership. He noted Lilly's acquisitions, including Centessa. This keeps investor attention on biotech M&A, which can lift CVR expectations and similar stocks.

    It reflects ongoing market enthusiasm for biotech deals, which supports the value of Centessa's CVR and the sector.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

August 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.